ATYR

aTyr Pharma

ATYR

Market cap $591M

Overview Fund Activity

6.03 USD

+0.77

14.64%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

6.25

+0.22

3.65%

1 day

14.64%

5 days

7.68%

1 month

15.3%

3 months

11.05%

6 months

69.86%

Year to date

54.22%

1 year

222.46%

5 years

59.95%

10 years

-97.7%

About: aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Employees: 59

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

80% more capital invested

Capital invested by funds: $187M [Q1] → $336M (+$150M) [Q2]

76% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 29

54% more call options, than puts

Call options by funds: $5.88M | Put options by funds: $3.81M

26% more funds holding

Funds holding: 86 [Q1] → 108 (+22) [Q2]

5.04% more ownership

Funds ownership: 69.5% [Q1] → 74.54% (+5.04%) [Q2]

4% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 24

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$17

182% upside

Avg. target

$21

248% upside

High target

$25

315% upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Jefferies Roger Song	$17	Buy Maintained	22 Aug 2025
Wells Fargo Derek Archila	$25	Overweight Maintained	20 Jun 2025

See Analyst Rankings

Financial journalist opinion

The Motley Fool

1 Small-Cap Biotech Stock Poised for a Breakout

Some prominent biotech companies tend to capture the majority of investors' and analysts' attention compared to their industry peers. aTyr Pharma (ATYR 2.10%), a small-cap, clinical-stage biotech, doesn't belong to that group.

1 Small-Cap Biotech Stock Poised for a Breakout

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted three employees nonstatutory stock options to purchase an aggregate of 62,400 shares of aTyr's common stock, each with an exercise price of $5.71 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on September 3, 2025, the effective date of the grants.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced second quarter 2025 results and provided a corporate update. “With the recent completion of the last patient visit in our Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), we are on track to report topline data in mid-September,” said Sanjay S.

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the last patient has completed their last visit in the Company's Phase 3 EFZO-FIT™ study of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease. The Company expects to report topline results from this study in the third quarter of 2025.

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000 ® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution. The Russell 3000® Index tracks the performance of the largest 3,000 publicly traded U.S. companies and serves as a broad benchmark for the U.S. equity market.

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses.

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

aTyr Pharma to Present at Upcoming Investor Conferences

SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod in pulmonary sarcoidosis is higher than previously estimated with increased morbidity.

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Compensation Committee of aTyr's Board of Directors has granted two employees nonstatutory stock options to purchase an aggregate of 36,200 shares of aTyr's common stock, each with an exercise price of $3.00 per share, which is equal to the closing price of aTyr's common stock on the Nasdaq Capital Market on May 15, 2025, the effective date of the grants. These stock awards were granted as an inducement material to the new employees entering into employment with aTyr in accordance with Nasdaq Listing Rule 5635(c)(4) and were made pursuant to the aTyr Pharma, Inc. 2022 Inducement Plan.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

Preclinical data demonstrate ATYR0101's unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit.

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

See News Rankings

Charts implemented using Lightweight Charts™